LGC, Fordham, Cambridgeshire, UK.
GIE LCH, Laboratoire des Courses Hippiques, Verrières-le-Buisson, France.
Drug Test Anal. 2024 Feb;16(2):112-126. doi: 10.1002/dta.3521. Epub 2023 Jun 1.
Boldenone is an anabolic-androgenic steroid (AAS) that is prohibited in equine sports. However, in certain situations, it is endogenous, potentially formed by the microbes in urine. An approach to the differentiation based on the detection of the biomarkers Δ1-progesterone, 20(S)-hydroxy-Δ1-progesterone and 20(S)-hydroxyprogesterone was assessed, and their concentrations were monitored in the urine of untreated female horses (n = 291) alongside boldenone, boldienone, testosterone and androstenedione. Using an ultra-sensitive analytical method, boldenone (256 ± 236 pg/mL, n = 290) and the biomarkers (Δ1-progesterone up to 57.6 pg/mL, n = 8; 20(S)-hydroxy-Δ1-progesterone 85.3 ± 181 pg/mL, n = 130; 20(S)-hydroxyprogesterone 43.5 ± 92.1 pg/mL, n = 158) were detected at low concentrations. The ex vivo production of Δ1-steroids was artificially induced following the storage of urine samples at room temperature for 7 days in order to assess the concentrations and ratios of the monitored steroids. The administration of inappropriately stored feed source also resulted in an increase in 20(S)-hydroxy-Δ1-progesterone concentrations and the biomarker ratios. Using the results from different datasets, an approach to differentiation was developed. In situations where the presence of boldenone exceeds a proposed action limit of 5 ng/mL, the presence of the biomarkers would be investigated. If Δ1-progesterone is above 50 pg/mL or if 20(S)-hydroxy-Δ1-progesterone is above 100 pg/mL with the ratio of 20(S)-hydroxy-Δ1-progesterone:20(S)-hydroxyprogesterone greater than 5:1, then this would indicate ex vivo transformation or consumption of altered feed rather than steroid administration. There remains a (small) possibility of a false negative result, but the model increases confidence that adverse analytical findings reported in female horses are caused by AAS administrations.
宝丹酮是一种禁用的同化雄性甾体激素(AAS),存在于赛马运动中。然而,在某些情况下,它可能是内源性的,由尿液中的微生物产生。本研究评估了一种基于检测生物标志物 Δ1-孕酮、20(S)-羟基-Δ1-孕酮和 20(S)-羟基孕酮的区分方法,并监测了未经处理的雌性马尿液中的浓度(n=291),同时还监测了宝丹酮、宝丹酮、睾酮和雄烯二酮的浓度。使用超灵敏分析方法,检测到低浓度的宝丹酮(256±236pg/mL,n=290)和生物标志物(Δ1-孕酮最高 57.6pg/mL,n=8;20(S)-羟基-Δ1-孕酮 85.3±181pg/mL,n=130;20(S)-羟基孕酮 43.5±92.1pg/mL,n=158)。为了评估监测甾体激素的浓度和比值,将尿液样本在室温下储存 7 天以诱导体外产生 Δ1-甾体。不适当储存的饲料来源的给药也会导致 20(S)-羟基-Δ1-孕酮浓度和生物标志物比值升高。使用来自不同数据集的结果,开发了一种区分方法。如果存在的宝丹酮超过建议的 5ng/mL 行动限值,则将调查生物标志物的存在。如果 Δ1-孕酮高于 50pg/mL,或者如果 20(S)-羟基-Δ1-孕酮高于 100pg/mL,且 20(S)-羟基-Δ1-孕酮与 20(S)-羟基孕酮的比值大于 5:1,则表明是体外转化或食用了改变的饲料,而不是甾体激素的给药。仍然存在假阴性结果的可能性,但该模型增加了对报告的雌性马中不良分析结果是由 AAS 给药引起的信心。